Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
ABL Bio
Sort By
Newest First
1 / 1
1 / 1
Immuno-Oncology
ABL Bio Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody(TM) Platform for Novel Immune Check Point Bispecifics for $220 Million
WuXi Biologics
PR-M02-19-NI-067
Feb 28, 2019
Partnership
WuXi Biologics and ABL Bio Enter an Exclusive Development and Clinical Manufacturing Partnership for Multiple Bispecific Antibodies
WuXi Biologics
PR-M12-18-NI-003
Dec 03, 2018
Global Collaboration
ABL Bio and I-Mab Biopharma Announce Global Collaboration on Innovative Bispecific Antibodies
ABL Bio
PR-M08-18-NI-005
Aug 01, 2018
Global Collaboration
I-Mab Biopharma and ABL Bio Announce Global Collaboration on Innovative Bispecific Antibodies
I-Mab
PR-M07-18-NI-107
Jul 31, 2018
